A study of IRESSA in relapsed and refractory small cell lung cancer
Study identifier:1839IL/0559
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Phase II study of Iressa in relapsed and refractory Small Cell Lung Cancer
Medical condition
Small cell lung cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
Gefitinib
Sex
All
Actual Enrollment
56
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Sept 2004
Primary Completion Date: -
Study Completion Date: 01 Mar 2007
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jun 2008 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Iressa Medical Science Director
AstraZeneca
